Complement Activation in the Treatment of B-Cell Malignancies

Complement Activation in the Treatment of B-Cell Malignancies

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor...

Full description

Bibliographic Details
Main Authors: Clive S. Zent, Jonathan J. Pinney, Charles C. Chu, Michael R. Elliott
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Antibodies
Subjects:
complement
cytotoxicity
phagocytosis
monoclonal antibody
B-cell lymphoma
chronic lymphocytic leukemia (CLL)
Online Access:https://www.mdpi.com/2073-4468/9/4/68

Internet

https://www.mdpi.com/2073-4468/9/4/68

Similar Items